226 related articles for article (PubMed ID: 32130966)
1. Renal Toxicity of Systemic Therapy for Renal Cell Carcinoma.
Jaimes EA
Semin Nephrol; 2020 Jan; 40(1):49-58. PubMed ID: 32130966
[TBL] [Abstract][Full Text] [Related]
2. Renal toxicity of targeted therapies for renal cell carcinoma in patients with normal and impaired kidney function.
Mielczarek Ł; Brodziak A; Sobczuk P; Kawecki M; Cudnoch-Jędrzejewska A; Czarnecka AM
Cancer Chemother Pharmacol; 2021 Jun; 87(6):723-742. PubMed ID: 33768301
[TBL] [Abstract][Full Text] [Related]
3. Nephrotic-range proteinuria in a patient with a renal allograft treated with sorafenib for metastatic renal-cell carcinoma.
Jonkers IJAM; van Buren M
Clin Exp Nephrol; 2009 Aug; 13(4):397-401. PubMed ID: 19381758
[TBL] [Abstract][Full Text] [Related]
4. Modern Systemic Therapy for Metastatic Renal Cell Carcinoma of the Clear Cell Type.
Parikh M; Lara PN
Annu Rev Med; 2018 Jan; 69():209-221. PubMed ID: 29144835
[TBL] [Abstract][Full Text] [Related]
5. Acute tubulointerstitial nephritis and IgM deposits on glomerular capillary walls after immunotherapy with nivolumab for metastatic renal cell carcinoma.
Irifuku T; Satoh A; Tani H; Mandai K; Masaki T
CEN Case Rep; 2020 Feb; 9(1):48-54. PubMed ID: 31605271
[TBL] [Abstract][Full Text] [Related]
6. Management of treatment-related toxicity with targeted therapies for renal cell carcinoma: evidence-based practice and best practices.
Appleby L; Morrissey S; Bellmunt J; Rosenberg J
Hematol Oncol Clin North Am; 2011 Aug; 25(4):893-915. PubMed ID: 21763973
[TBL] [Abstract][Full Text] [Related]
7. Renal damage secondary to check-point inhibitors.
Moliz C; Cavero T; Morales E; Gutiérrez E; Alonso M; Praga M
Nefrologia (Engl Ed); 2020; 40(2):206-208. PubMed ID: 31615688
[No Abstract] [Full Text] [Related]
8. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
[TBL] [Abstract][Full Text] [Related]
9. Renal protection in hypertensive patients: selection of antihypertensive therapy.
Wenzel RR
Drugs; 2005; 65 Suppl 2():29-39. PubMed ID: 16398060
[TBL] [Abstract][Full Text] [Related]
10. Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma.
Bendtsen MAF; Grimm D; Bauer J; Wehland M; Wise P; Magnusson NE; Infanger M; Krüger M
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28796163
[TBL] [Abstract][Full Text] [Related]
11. A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer.
Albiges L; Choueiri T; Escudier B; Galsky M; George D; Hofmann F; Lam T; Motzer R; Mulders P; Porta C; Powles T; Sternberg C; Bex A
Eur Urol; 2015 Jan; 67(1):100-110. PubMed ID: 24841777
[TBL] [Abstract][Full Text] [Related]
12. VEGF inhibition, hypertension, and renal toxicity.
Hayman SR; Leung N; Grande JP; Garovic VD
Curr Oncol Rep; 2012 Aug; 14(4):285-94. PubMed ID: 22544560
[TBL] [Abstract][Full Text] [Related]
13. Uncontrolled Hypertension and Oncology: Clinical Tips.
Kalaitzidis RG; Elisaf MS
Curr Vasc Pharmacol; 2017; 16(1):23-29. PubMed ID: 28413967
[TBL] [Abstract][Full Text] [Related]
14. Mammalian Target of Rapamycin Inhibitor Monotherapy: Efficacy in Renal Transplantation.
Franco A; Más-Serrano P; Perez Contreras J; Jiménez L; Rodriguez D; Olivares J
Transplant Proc; 2015 Oct; 47(8):2364-7. PubMed ID: 26518928
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin system inhibitors and survival in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: A pooled secondary analysis of clinical trials.
Sorich MJ; Kichenadasse G; Rowland A; Woodman RJ; Mangoni AA
Int J Cancer; 2016 May; 138(9):2293-9. PubMed ID: 26685869
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin Inhibitors as Treatment of Sunitinib/Pazopanib-induced Hypertension in Metastatic Renal Cell Carcinoma.
Penttilä P; Rautiola J; Poussa T; Peltola K; Bono P
Clin Genitourin Cancer; 2017 Jun; 15(3):384-390.e3. PubMed ID: 28089721
[TBL] [Abstract][Full Text] [Related]
17. Calcium channel blockers in the prevention of end stage renal disease: a review.
Derwa A; Peeters P; Vanholder R
Acta Clin Belg; 2004; 59(1):44-56. PubMed ID: 15065696
[TBL] [Abstract][Full Text] [Related]
18. Toxicities of targeted agents in advanced renal cell carcinoma.
Patel P; Srinivas S
Curr Clin Pharmacol; 2011 Aug; 6(3):181-8. PubMed ID: 21827392
[TBL] [Abstract][Full Text] [Related]
19. Acute interstitial nephritis, a potential predictor of response to immune checkpoint inhibitors in renal cell carcinoma.
Patel V; Elias R; Formella J; Schwartzman W; Christie A; Cai Q; Malladi V; Kapur P; Vazquez M; McKay R; Pedrosa I; Hannan R; Hammers H; Brugarolas J
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33139246
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?
Perazella MA; Shirali AC
Kidney Int; 2020 Jan; 97(1):62-74. PubMed ID: 31685311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
